AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05480319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDICARS
Description: The investigators propose to (1) Embed the EDICAS into our hospital information system (HIS) in real-time at ED triage to identify high-risk patients (EDICAS 6+); and (2) Distribute wearable smart wristbands to high-risk patients to augment vital signs monitoring and send alerts based on GBTM results. The detection and intervention components together form the rapid response system, the Emergency Department In-hospital Cardiac Arrest Response System (EDICARS).
Study NCT04933370 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stimulation parameters
Description: Different device stimulation parameters
Study NCT04933370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation parameters
Description: Different device stimulation parameters
Study NCT05480319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care will be assigned to this arm. No additional interventions.
Study NCT04856657 — intervention group
Intervention type: DEVICE
Intervention: Transcranial alternating current stimulation
Description: The tACS will be applied with a current of 1-2 mA (milliamperes) via two saline soaked electrode sponges (25 cm²) applied to the back of the head. The anode will be located at Oz and the cathode will be located at Cz.
Study NCT05253508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: A digital nerve block by injections to the base of the finger
Study NCT05176457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication tool PICT'REA
Description: The pictograms communication tool PICT'REA will be available to patients with invasive ventilation systems preventing them from speaking
Study NCT05193565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8ng/mL
Study NCT05193565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Up to 1g BID(total 2g daily), PO
Study NCT06416163 — intervention group
Intervention type: OTHER
Intervention: Prospective
Description: Collection of prospective data all ready available for participant
Study NCT05774327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Roller
Description: Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. For 6 weeks, in addition to foot core exercises, myofascial release will be applied with foam roller 2 days a week. Myofascial release application areas; thoracolumbal fascia, iliotibial band, hamstring, gastro-soleus, peroneal, plantar fascia.
Study NCT05774327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Core Exercises
Description: Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. Foot core exercises; short foot exercise, toe flexion exercise, heel lift exercise,toe abduction exercise, big toe and other toes extension exercise, front swing exercise, back walking exercises. Participants will do the exercises with the researcher two days a week and the other days follow-up will be provided through the online platform.
Study NCT05104593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention tested (CAREPATH)
Description: The intervention tested will be the CAREPATH system. CAREPATH consists of an integrated, patient-centred, flexible and modular system that will provide a viable solution for the improvement of the management of multimorbid elderly patients with Mild Cognitive Impairment or mild dementia, with the help of clinicians. CAREPATH will act on patients and their informal caregivers, and its main objective is to empower multimorbid patients with MCI or mild dementia to manage their health condition together with their informal caregiver by providing assistance and reinforcement to follow their individual care plans, so independence and quality of life will increase for both of them. The intervention will provide a personalized care plan and activities proposal (treatment, activities proposal, lifestyle changes, referrals etc.) to patients and caregivers, considering the various sources of patient data available through the CAREPATH platform, and with the help of clinicians.
Study NCT05119803 — intervention group
Intervention type: DEVICE
Intervention: Spinal Mouse (IDIAG M360 )
Description: This device is an electronic computer-aided measuring december that measures the range of motion of the spine, evaluates the angle and shape of the spine in the sagittal and frontal planes. The device provides data to the computer via Bluetooth, and the measured curvatures are displayed on the computer screen. The method has no medical risks or dangers. The device has two rotating wheels that follow the spinous protrusions of the spine, and the distance and angle measurements are transferred from the device to the computer.
Study NCT05006742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CB study arm
Description: Included patients are randomized to receive cryobiopsy
Study NCT05006742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FB-CB study arm
Description: Included patients are randomized to receive forceps biopsy and cryobiopsy within the same session
Study NCT05950646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be infused at a rate of 0.01 ml/ kg/h (0.02 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
Study NCT05950646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine will be infused at a rate of 0.01 ml/ kg/h (5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
Study NCT05950646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
Study NCT05321446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoHand(TM)
Description: The GoHand(TM) is a therapeutic wearable that provides positive auditory feedback when the wrist and hand moves optimally during execution of dexterity tests and everyday movements.
Study NCT05119803 — intervention group
Intervention type: OTHER
Intervention: Nine Hole Peg Test
Description: The nine-hole peg test is a simple, fast and manual skill test that has been proven to be valid and reliable in measuring upper limb function in Parkinson's patients. While the patient is sitting, he is asked to insert nine sticks into the holes of the test box with nine holes one by one as fast as possible and remove them back when he is finished
Study NCT05166707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIXINK OC Free
Description: OC Free is a 6-week ERP-based intervention to deliver Exposure and Response Prevention (ERP) to reduce the anxiety from obsessive thoughts and compulsive rituals.
Study NCT05136833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI® vaccine
Description: Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
Study NCT05136833 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be used as a placebo.
Study NCT06332872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ivermectin
Description: Oral formulation (3mg tablet) Dosage: 2 single doses of 200 mcg/kg given 7 days apart
Study NCT06332872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% dimenticone liquid gel
Description: topical formulation (liquid gel) only 1 application
Study NCT06266793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium Laser
Description: Assigned to be treated using the Lumenis Pulse 120H Moses 2.0 Holmium Laser.
Study NCT06487546 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ergothioneine
Description: This is a 1-arm study in which participants will take ergothioneine daily with dose range of 5 mg to 25 mg daily. Blood levels of ergothioneine will be monitored while taking daily ergothioneine and after ergothioneine is stopped.
Study NCT06266793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium Laser
Description: Assigned to be treated using the Olympus Soltive Thulium SuperPulsed Fiber Laser
Study NCT05617521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)
Description: Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device
Study NCT05617521 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)
Description: Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.
Study NCT06220006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Catheter ablation
Study NCT06220006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: Catheter ablation
Study NCT05408260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo HHUS
Study NCT05408260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated Breast Ultrasound
Description: Undergo ABUS
Study NCT06393335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
Study NCT05729893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: root canal sealers
Description: different sealer used in obturating root canals (resin and bio ceramic)
Study NCT05559307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xingnaojing injection
Description: Xingnaojing injection 20 ml+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 7 days.
Study NCT05364333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
Study NCT05364333 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
Study NCT05437705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100\* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
Study NCT05437705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100\* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
Study NCT05297318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypotension prediction index guided
Description: patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
Study NCT05297318 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: without hypotesion prediction index guided
Description: patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
Study NCT05237206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUPLEXA
Description: PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.
Study NCT05321446 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GoHand(TM)
Description: The GoHand(TM) is a therapeutic wearable that provides positive auditory feedback when the wrist and hand moves optimally during execution of dexterity tests and everyday movements.
Study NCT05636800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swift System
Description: Localized microwave energy applied to the distinct AK lesion. Each subject will receive treatment for a maximum of 2 visits (4-week interval between treatment).~For AK lesions assessed as Thin AK (Olsen Grades 1 and 2): Set at 3W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions). There will be approximately 20 seconds between each repeat dose.~For AK lesions assessed as Thick AK (Olsen Grade 3): Set at 4W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions).~As the AK lesions may be larger than 3mm in diameter, the dose administered to one AK lesion may require overlapping applications with the applicator tip. Ensure there is approximately 20 seconds between each repeat dose administered
Study NCT05539989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002 Vaccine
Description: 0.1 mL (2-8x10\^5 CFU)
Study NCT05539989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: 0.1mL (0.075 Mycobacterium bovis)
Study NCT05539989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mL (sodium chloride for injection 0.9%)
Study NCT05033405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEURO-LINGUISTIC PROGRAMMING (NLP)
Description: ● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
Study NCT06210360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: 50 mg/m² on Day 1 of a 14 day cycle
Study NCT06210360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan liposome injection
Description: 50 mg/m² on Day 1 of a 14 day cycle
Study NCT06210360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60 mg/m² on Day 1 of a 14 day cycle
Study NCT06210360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 60 mg/m² on Day 1 of a 14 day cycle
Study NCT06210360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m² continuous IV infusion in 46 h
Study NCT06210360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m² continuous IV infusion in 46 h
Study NCT06210360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: 400 mg/m² on Day 1 of a 14 day cycle
Study NCT06210360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV
Description: 400 mg/m² on Day 1 of a 14 day cycle
Study NCT04944680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation therapy
Description: Transcranial Direct Current Stimulation with two saline-soaked electrodes (5cm x 7cm) is applied by our occupational therapist. The anode is placed on the ipsilesional primary motor cortex (C3/C4). The cathode is placed on the contralesional shoulder. The current is 1.5 milliampere and lasts 20 minutes.
Study NCT04944680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery therapy
Description: Stroke patients are asked to watch a video about the upper extremity movement. The video lasts 20 minutes. The contents are as follows: the patients are asked to relax the muscles for the first 2 minutes; the action refers to shoulder flexion and extension, elbow flexion and extension, forearm pronation and supination, wrist flexion and extension, finger flexion and extension, and corresponding daily functional activities for 16min; the patients are asked to relax their mind and body for the last 2 minutes.
Study NCT04944680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation and motor imagery therapy
Description: The treatment parameters are the same as the above. It should be emphasized that the participants sit and perform the motor imagery task while receiving Transcranial Direct Current Stimulation.
Study NCT06297785 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gut-directed hypnotherapy
Description: Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8 sessions), will be given online in a group setting.The hypnosis treatment is administered by a nurse specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment is based on the North Carolina protocol. Patients will assess gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
Study NCT04870697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT intervention
Description: The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer.
Study NCT04870697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care in this study setting includes providing general information, education, psychological support, and consultation.
Study NCT05772585 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection (1 to 4 times for each patient) in order to perform metabolomic analyses of the plasmatic fingerprints of patients with hepatic encephalopathy
Study NCT05170867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hafnia alvei HA4597™
Description: One capsule of probiotic supplement, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the dietary supplement contain 5x107 CFU of Hafnia alvei HA4597™, 5 mg of zinc and 20 μg of chromium.
Study NCT05170867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of placebo, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the placebo contain 5 mg of zinc and 20 μg of chromium.
Study NCT04546828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, and Nab-Paclitaxe
Description: * Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days .
Study NCT06476054 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optimal timing for laparoscopic cholecystectomy
Description: To compare early and late cholecystectomy after cholecystostomy.
Study NCT05600075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: microneedling with topical glycolic acid 35%.
Description: 15 patients will be subjected to microneedling with topical glycolic acid 35%. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
Study NCT05600075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: microneedling with topical human insulin solution.
Description: 15 patients will be subjected to microneedling with topical human insulin solution. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
Study NCT05282914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of UI058
Description: UI058 1Tab/day for 7days
Study NCT05282914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of UIC202004
Description: UIC202004 1Tab/day for 7days